Vir Biotechnology Reports Promising Phase 2 Results for Chronic Hepatitis B Treatments

Vir Biotechnology Reports Promising Results for Chronic Hepatitis B Treatment

Vir Biotechnology, Inc. announces positive results from the MARCH Phase 2 clinical study, focusing on the treatment of chronic hepatitis B (CHB) using two investigational therapies, tobevibart and elebsiran, both alone and in combination with pegylated interferon alfa (PEG-IFNα). The study's findings are significant, particularly regarding the rates of hepatitis B surface antigen (HBsAg) loss among participants. The data reveals that individuals with lower baseline HBsAg levels (<1000 IU/mL) experience notably higher seroclearance rates, with 39% of participants in the doublet regimen achieving HBsAg loss and 46% in the triplet regimen. This represents a substantial advancement, as current treatments for CHB do not provide a definitive cure.

The MARCH study involved a total of 78 participants, with 51 receiving the doublet regimen and 27 the triplet regimen. Notably, a total of 16% in the doublet arm and 22% in the triplet arm achieved HBsAg loss by the end of treatment. In a promising development, half of the participants in the doublet regimen who achieved HBsAg loss also demonstrated anti-HBs seroconversion, indicating a potential for long-term immunity. The results underscore the potential of combining these therapeutics to enhance treatment efficacy, addressing a significant unmet medical need in a condition that affects approximately 254 million people globally, contributing to over a million deaths annually.

The urgency for effective treatments for chronic hepatitis B is underscored by the limitations of existing therapies, which primarily manage the virus rather than eradicate it. Vir Biotechnology's commitment to advancing research in this area is evident, with plans to present detailed findings from the MARCH study at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® on November 18. An investor conference call is scheduled for November 19, where the company aims to delve deeper into the implications of these promising results for future hepatitis B therapies.

In addition to the positive trial results, Vir Biotechnology’s ongoing research reflects a dedicated effort to address the global health crisis posed by chronic hepatitis B. The innovative combination of tobevibart and elebsiran with PEG-IFNα marks a critical step towards potentially curative treatments. As the company prepares for its upcoming presentations, the medical community anticipates further insights into the implications of these findings for patient care in chronic hepatitis B management.